AFMDのチャート
AFMDの企業情報
| symbol | AFMD |
|---|---|
| 会社名 | Affimed N.V. （アフィメド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia. アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。 affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli |
| 本社所在地 | Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU |
| 代表者氏名 | Thomas Hecht トーマス・ヘクト |
| 代表者役職名 | Chairman of the Supervisory Board |
| 電話番号 | +49 6221-67-4360 |
| 設立年月日 | 41760 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.affimed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/afmd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -34.24747 |
| 終値（lastsale） | 4.62 |
| 時価総額（marketcap） | 288242114.16 |
| 時価総額 | 時価総額（百万ドル） 218.36520 |
| 売上高 | 売上高（百万ドル） 2.05078 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 170.73193 |
| 当期純利益 | 当期純利益（百万ドル） -35.31480 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense). |
AFMDのテクニカル分析
AFMDのニュース
Affimed N.V. (AFMD) Q1 2023 Earnings Call Transcript 2023/05/23 16:36:04 Seeking Alpha
Affimed N.V. (NASDAQ:NASDAQ:AFMD) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ETCompany ParticipantsAlex Fudukidis - Director of Investor RelationsAdi Hoess - Chief Executive…
Affimed Gains FDA Nod for Lymphoma IND Combination 2023/05/23 12:27:51 TipRanks
Shares of biopharmaceutical company Affimed (NASDAQ:AFMD) are on the rise today after the U.S. Food and Drug Administration (FDA) gave a go-ahead t…
Earnings Scheduled For May 23, 2023 2023/05/23 10:58:43 Benzinga
Companies Reporting Before The Bell • ATRenew (NYSE: RERE ) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million. • Endava (NYSE: DAVA ) is expected to report quarterly earnings at $0.66 per share on revenue of $251.01 million. • Dick''s Sporting Goods (NYSE: DKS ) is estimated to report quarterly earnings at $3.18 per share on revenue of $2.80 billion. • Lowe''s Companies (NYSE: LOW ) is estimated to report quarterly earnings at $3.44 per share on revenue of $21.60 billion. • T2 Biosystems (NASDAQ: TTOO ) is expected to report quarterly loss at $1.20 per share on revenue of $2.33 million. • Kingsoft Cloud Hldgs (NASDAQ: KC ) is projected to report quarterly loss at $0.23 per share on revenue of $282.80 million. • Zepp Health (NYSE: ZEPP ) is projected to report quarterly loss at $0.02 per share on revenue of $122.93 million. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.21 per share on revenue of $5.69 million. • Vipshop Holdings (NYSE: VIPS ) is likely to report quarterly earnings at $0.37 per share on revenue of $3.72 billion. • Navios Maritime Partners (NYSE: NMM ) is likely to report quarterly earnings at $3.16 per share on revenue of $312.00 million. • …
Affimed N.V.: Q1 Earnings Snapshot 2023/05/23 10:37:06 WTOP
HEIDELBERG, Germany (AP) — HEIDELBERG, Germany (AP) — Affimed N.V. (AFMD) on Tuesday reported a loss of $34.3 million in…
Affimed N.V.: Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress 2023/05/23 10:36:00 Finanz Nachrichten
AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphom…
Wells Fargo Assumes Affimed Therapeutics at Overweight 2023/03/27 11:56:16 Investing.com
https://www.investing.com/news/pro/affimed-therapeutics-receives-investment-bank-analyst-rating-update-432SI-3040892
Affimed Therapeutics PT Lowered to $1 at Stifel 2023/03/24 11:34:10 Investing.com
https://www.investing.com/news/pro/affimed-therapeutics-pt-lowered-to-1-at-stifel-432SI-3038997
Affimed N.V. (AFMD) Q4 2022 Earnings Call Transcript 2023/03/23 19:04:05 Seeking Alpha
Affimed N.V. (NASDAQ:NASDAQ:AFMD) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ETCompany ParticipantsAlex Fudukidis - Director of Investor RelationsAdi Hoess - Chief Executive…
Earnings Scheduled For March 23, 2023 2023/03/23 12:10:27 Benzinga
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ: CGTX ) is likely to report earnings for its fourth quarter. • Affimed (NASDAQ: AFMD ) is expected to report quarterly loss at $0.21 per share on revenue of $7.38 million. • Energy Focus (NASDAQ: EFOI ) is estimated to report quarterly loss at $0.26 per share on revenue of $4.20 million. • AstroNova (NASDAQ: ALOT ) is projected to report earnings for its fourth quarter. • Hywin Holdings (NASDAQ: HYW ) is expected to report earnings for its first quarter. • Perma-Fix Envirn Servs (NASDAQ: PESI ) is likely to report earnings for its fourth quarter. • Mogo (NASDAQ: MOGO ) is likely to report quarterly loss at $0.09 per share on revenue of $16.20 million. • Exscientia (NASDAQ: EXAI ) is projected to report quarterly loss at $0.32 per share on revenue of $8.26 million. • Movado Group (NYSE: MOV ) is expected to report quarterly earnings at $0.86 per share on revenue of $184.40 million. • REX American Resources (NYSE: REX ) is expected to report quarterly earnings at $0.25 per share on revenue of $210.15 million. • Altisource Asset Mgmt (AMEX: AAMC ) is projected to report earnings for its fourth quarter. • Priority Tech Holdings (NASDAQ: PRTH ) is projected to report quarterly loss at $0.07 per share on revenue of $165.25 million. • BRP (NASDAQ: DOOO ) is likely to report quarterly earnings at $2.76 per share on revenue of $2.19 billion. • Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE: CWEB ) is projected to report quarterly loss at $0.05 per share on revenue of $33.70 million. • Gambling.com Gr (NASDAQ: GAMB ) is expected to report quarterly earnings at $0.07 per share on revenue of $18.27 million. • General Mills (NYSE: GIS ) is projected to report quarterly earnings at $0.91 per share on revenue of $4.94 billion. • Darden Restaurants (NYSE: DRI ) is estimated to report quarterly earnings at $2.21 per share on …
Affimed N.V. (AFMD) can beat the pack with these strategies 2023/02/23 16:24:00 US Post News
In Wednesday’s session, Affimed N.V. (NASDAQ:AFMD) marked $0.97 per share, down from $0.99 in the previous session. While Affimed N.V. has underperformed by -2.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -77.09%, with highs and lows ranging from $5.10 to $0.98, whereas […]
Affimed N.V. (AFMD) can beat the pack with these strategies 2023/02/23 16:24:00 US Post News
In Wednesday’s session, Affimed N.V. (NASDAQ:AFMD) marked $0.97 per share, down from $0.99 in the previous session. While Affimed N.V. has underperformed by -2.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AFMD fell by -77.09%, with highs and lows ranging from $5.10 to $0.98, whereas […]
Alluring stocks: Affimed N.V. (NASDAQ:AFMD -2.22%), Ambrx Biopharma Inc. (NYSE:AMAM 0.22%) 2023/02/23 13:50:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Alluring stocks: Affimed N.V. (NASDAQ:AFMD -2.22%), Ambrx Biopharma Inc. (NYSE:AMAM 0.22%) appeared first on Stocks Equity .
Current Investor’s Watch List: Bit Digital, Inc. (NASDAQ:BTBT), Affimed N.V. (NASDAQ:AFMD) 2023/02/22 18:18:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Current Investor’s Watch List: Bit Digital, Inc. (NASDAQ:BTBT), Affimed N.V. (NASDAQ:AFMD) appeared first on Stocks Equity .
Spellbinding stocks: Affimed N.V. (NASDAQ:AFMD -3.04%), Avino Silver & Gold Mines Ltd. (AMEX:ASM -3.42%) 2023/02/22 07:47:11 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Spellbinding stocks: Affimed N.V. (NASDAQ:AFMD -3.04%), Avino Silver & Gold Mines Ltd. (AMEX:ASM -3.42%) appeared first on Stocks Equity .
Is Affimed N.V. (NASDAQ: AFMD) Stock Set To Rise More? 2023/02/21 19:00:00 Marketing Sentinel
In the latest trading session, 0.56 million Affimed N.V. (NASDAQ:AFMD) shares changed hands as the company’s beta touched 2.53. With the company’s most recent per share price at $1.00 changed hands at -$0.02 or -1.47% at last look, the market valuation stands at $145.90M. AFMD’s current price is a discount, trading about -410.0% off its … Is Affimed N.V. (NASDAQ: AFMD) Stock Set To Rise More? Read More »